aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in 2007 and headquartered in San Diego, California, Organovo Holdings, Inc. is a pioneering biotech company specializing in 3D bioprinting technology. The company's core mission is to create functional, three-dimensional human tissues for medical research and therapeutic applications. Organovo's innovative bioprinting solutions are designed to enhance drug discovery processes and offer potential advancements in regenerative medicine. Serving a global market, the company aims to revolutionize the way researchers and clinicians approach tissue engineering and disease modeling.
Notable figures associated with Organovo include Taylor J. Crouch, who has served as CEO. The company is publicly traded on Nasdaq under the ticker symbol ONVO and is a component of the Russell 2000 Index. Organovo has achieved significant milestones, including presenting groundbreaking data at major medical conferences such as Digestive Disease Week. With total assets of over $62 million as of 2016 and a revenue of $4.23 million in 2017, Organovo continues to make a substantial impact in the biotech industry by advancing the capabilities of 3D bioprinting technology.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Medical Research, Bioprinting
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Research
Geographic Exposure
Global
When was Organovo founded?
Organovo was founded in 2011.
Where is Organovo’s headquarters located?
Organovo’s headquarters is located in DE, US.
When was Organovo’s last funding round?
Organovo’s most recent funding round was for $22M (USD) in January 2021.
How many employees does Organovo have?
Organovo has 39 employees as of Feb 6, 2024.
How much has Organovo raised to-date?
As of July 05, 2023, Organovo has raised a total of $112.3M (USD) since Jan 29, 2021.
Add Comparison
Total Raised to Date
$112.3M
USD
Last Update Jan 29, 2021
Last Deal Details
$22M
USD
Jan 29, 2021
Post Ipo Equity
Total Employees Over Time
39
As of Feb 2024
Organovo Address
Delaware
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts